UBE2I Antibodies

SUMO-conjugating enzyme UBC9 (UBE2I)

Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3, SUMO4 and SUMO1P1/SUMO5 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the Support of an E3 ligase like RANBP2, CBX4 and ZNF451.

Can catalyze the formation of poly-SUMO chains.

Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation.

Gene Information

Human
Gene Name:	UBE2I
Uniprot:	P63279
Entrez:	7329

Family

Belongs to:
ubiquitin-conjugating enzyme family

Alternative Names

C358B7.1; EC 6.3.2; EC 6.3.2.-; p18; SUMO-1-protein ligase; SUMO-protein Ligase; Ubc9; UBC9SUMO-conjugating enzyme UBC9; UBCE9; UBE2I; Ubiquitin carrier protein 9; Ubiquitin carrier protein I; ubiquitin conjugating enzyme 9; Ubiquitin-conjugating enzyme E2 I; ubiquitin-conjugating enzyme E2I (homologous to yeast UBC9); ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast); ubiquitin-conjugating enzyme UbcE2A; ubiquitin-like protein SUMO-1 conjugating enzyme; ubiquitin-protein ligase E2I; Ubiquitin-protein ligase I

Molecular Weight

Mass (kDA):
18.007 kDA

Genomic Context

Human
Location:	16p13.3
Sequence:	16; NC_000016.10 (1309152..1327017)

Tissue Specificity

Expressed in heart, skeletal muscle, pancreas, kidney, liver, lung, placenta and brain. Also expressed in testis and thymus.

Subcellular Localizations

Nucleus. Cytoplasm. Mainly nuclear. In spermatocytes, localizes in synaptonemal complexes. Recruited by BCL11A into the nuclear body (By similarity).

Diseases

• Neoplasms
• Cell Transformation, Neoplastic
• Tissue Adhesions
• Microphthalmos
• Waardenburg Syndrome
• Monoclonal Gammapathies
• Monoclonal Gammopathy Of Undetermined Significance
• Carcinogenesis
• Carcinoma
• Neoplasms, Glandular And Epithelial
• Multiple Myeloma

• Feline Urological Syndrome
• Malignant Neoplasms
• Malignant Neoplasm Of Ovary
• Epithelial Ovarian Cancer
• Ovarian Neoplasm
• Plasma Cell Neoplasm

Interacting Proteins

• BHLHE40
• CHMP4B
• DAXX
• DNMT3B
• EDARADD

• ELK1
• GMCL1
• GOLGA2
• HDAC4
• IPO13

• PIAS2
• RANBP2
• RANGAP1
• RNF111
• RUVBL1

• RWDD3
• SETX
• SMAD4
• SOX10
• SUMO1

• SUMO1P1
• SUMO2
• TFAP2A
• TFAP2C
• TFCP2

• TP53
• UBA1
• UBA2
• ZBTB26
• ZCCHC7

• ZNF451

Pathways

• Cell Cycle
• Cell Adhesion
• Diplotene
• Mitosis
• Protein Sumoylation
• Oocyte Growth
• Dna Recombination
• M Phase
• Metaphase
• Localization
• Double-strand Break Repair
• Spermatogenesis
• Oocyte Development

• Sensitization
• Coagulation
• Prophase
• Cell Growth
• Mrna Processing
• Pathogenesis
• Pachytene

PTMs

• Sumoylation

• Ubiquitination

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/UBE2I

Boster Bio UBE2D4 Antibody - Best Uses Of The UBE2I Marker

If you're looking for a high-affinity UBE2I antigen antibody, then read this article. We will explain the differences between high-affinity primary antibodies and generic ones, as well as their uses. These antibodies are highly relevant to research and are used in numerous applications. The Boster antibodies have been well-cited in the scientific literature for over 25 years, and are well-validated for use in Western Blotting, Immunohistochemistry, and ELISA assays.

UBE2D4 Human Recombinant

The Boster Bio UBE2D4 Human recombinant marker is manufactured from E. coli and contains 167 amino acids. Its molecular mass is 18.8 kDa. The boster bio UBE2D4 human recombinant marker can be stored at 4degC, avoiding freeze-thail cycles. It is available for both human and mouse samples.

High-affinity primary antibodies

In a recent study, scientists reported the successful production of high-affinity primary antibodies against immunizing antigens in mice that express high levels of GANP, a new intranuclear factor. It plays an important role in the reconstruction of antibody genes. Using transgenic mice expressing high levels of GANP, researchers were able to produce antibodies with high affinity to immunizing antigens. This marker is related to the protein MCM3, a key component in DNA replication.

The UBE2I marker has the unique ability to increase the affinity of primary antibodies to specific antigens. Its affinity can be up to 106 times greater than that of other primary antibodies. Because of its high affinity, it is highly stable at higher temperatures than conventional antibodies. High-affinity primary antibodies using the UBE2I marker have a range of dissociation constants of 10-6 to 10-9 for various antigens.

Previously, we have reported on the use of the UBE2I marker to develop high-affinity antibodies. This marker can be used in a variety of applications, including immunohistochemistry and molecular biology. Its affinity has been demonstrated in several experiments, including the in vitro diagnostics (IFA) and immunohistochemistry. In these experiments, high-affinity antibodies containing UBE2I are extremely useful in identifying specific antigens in cells.

Generic antibodies

The discovery of a new class of monoclonal antibodies targeting the UBE2I marker has paved the way for more effective therapy in hepatocellular carcinoma (HCC). These antibodies target the enzyme's receptor, which is expressed in HCC cells. The UBE2I protein has been associated with a poor prognosis, inflammation, and tumor angiogenesis. Generic antibodies targeting the UBE2I marker may have a positive impact on HCC.

Human UBE2I is expressed as a purified recombinant fragment in E. coli. The observed molecular weight of the protein may differ from that predicted due to post-translational modifications, cleavages, relative charges, and experimental factors. This antibody is intended for research use only. It is guaranteed for one year from the date of receipt. The UBE2I marker is expressed on the surface of a human cell.